Trump Repeals Biden-Era Order on Prescription Drug Pricing

The move raises concerns over the future of Medicare drug price negotiations and potential cost increases for Americans.

President Trump rescinded Biden's executive order aimed at lowering prescription drug costs, creating uncertainty about future price reductions.
Biden's order had initiated Medicare programs, including a $2 cap on certain generic drugs, which may now face discontinuation or revision.
The Inflation Reduction Act's drug price negotiation provisions remain intact, with significant savings anticipated starting in 2026, unless altered by the new administration.
Concerns arise over whether Trump's administration, including key appointees, will actively defend or implement the existing drug pricing law amid ongoing legal challenges.
Experts highlight the potential for pharmaceutical companies to raise prices if regulatory measures promoting transparency and competition are weakened.